Drug Profile
Mycophenolate sodium controlled release - Novartis
Alternative Names: EC-MPS; ERL 080; ERL 080A; Mycophenolic acid - Novartis; MyforticLatest Information Update: 10 Dec 2021
Price :
$50
*
At a glance
- Originator Novartis
- Developer Novartis; University of Pittsburgh
- Class Benzofurans; Small molecules; Urologics
- Mechanism of Action Immunosuppressants; Inosine monophosphate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Renal transplant rejection
- No development reported Heart transplant rejection; Liver transplant rejection; Lupus nephritis
Most Recent Events
- 27 Jan 2017 Novartis has patent protection for mycophenolate sodium in USA and Europe (Novartis 20-F filed in 2017)
- 09 Jan 2014 First generic equivalent available in USA for Renal transplant rejection
- 18 Nov 2009 Novartis completes a phase II trial in Lupus nephritis in Hungary, France, Great Britain, Greece, Denmark, Italy and Spain (EudraCT2006-002107-13)